BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother 2016;16:483-95. [PMID: 27050932 DOI: 10.1586/14737175.2016.1173545] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Shah A, Northcutt J. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Ann Gen Psychiatry 2018;17:19. [PMID: 29760763 DOI: 10.1186/s12991-018-0190-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ballanger B, Bath KG, Mandairon N. Odorants: a tool to provide nonpharmacological intervention to reduce anxiety during normal and pathological aging. Neurobiol Aging 2019;82:18-29. [PMID: 31377537 DOI: 10.1016/j.neurobiolaging.2019.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Mochcovitch MD, da Rocha Freire RC, Garcia RF, Nardi AE. Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review. Clin Drug Investig 2017;37:737-43. [DOI: 10.1007/s40261-017-0528-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Werner FM, Coveñas R. Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and Neuropeptides. Curr Pharm Des 2019;25:388-95. [PMID: 30969164 DOI: 10.2174/1381612825666190410165243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Kennedy SH, Grouin JM, Cadour S, Robert V, Picarel-Blanchot F. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Hum Psychopharmacol 2018;33. [PMID: 29327372 DOI: 10.1002/hup.2646] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 De Berardis D, Fornaro M, Anastasia A, Vellante F, Olivieri L, Rapini G, Serroni N, Orsolini L, Valchera A, Carano A, Tomasetti C, Ventriglio A, Bustini M, Pompili M, Serafini G, Perna G, Iasevoli F, Martinotti G, Di Giannantonio M. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. Braz J Psychiatry 2020;42:317-21. [PMID: 32159712 DOI: 10.1590/1516-4446-2019-0690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother 2018;19:1057-70. [PMID: 30056792 DOI: 10.1080/14656566.2018.1491966] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
8 Xue W, Fu T, Zheng G, Tu G, Zhang Y, Yang F, Tao L, Yao L, Zhu F. Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters. CMC 2020;27:3830-76. [DOI: 10.2174/0929867325666181009123218] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
9 De Berardis D, Olivieri L, Nappi F, Rapini G, Vellante F, Matarazzo I, Serroni N, Di Giannantonio M. Vortioxetine and Aripiprazole Combination in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report. J Clin Psychopharmacol 2017;37:732-4. [DOI: 10.1097/jcp.0000000000000801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tomasetti C, Montemitro C, Fiengo AL, Santone C, Orsolini L, Valchera A, Carano A, Pompili M, Serafini G, Perna G, Vellante F, Martinotti G, Giannantonio MD, Kim Y, Nicola MD, Bellomo A, Ventriglio A, Fornaro M, Berardis DD. Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. CPD 2019;25:381-7. [DOI: 10.2174/1381612825666190312102444] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
11 Villas-Boas GR, Lavorato SN, Paes MM, de Carvalho PMG, Rescia VC, Cunha MS, de Magalhães-Filho MF, Ponsoni LF, de Carvalho AAV, de Lacerda RB, da S Leite L, da S Tavares-Henriques M, Lopes LAF, Oliveira LGR, Silva-Filho SE, da Silveira APS, Cuman RKN, de S Silva-Comar FM, Comar JF, do A Brasileiro L, Dos Santos JN, de Freitas WR, Leão KV, da Silva JG, Klein RC, Klein MHF, da S Ramos BH, Fernandes CKC, de L Ribas DG, Oesterreich SA. Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence. Pharmaceuticals (Basel) 2021;14:148. [PMID: 33673205 DOI: 10.3390/ph14020148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Mortensen JK, Andersen G. Pharmacological management of post-stroke depression: an update of the evidence and clinical guidance. Expert Opin Pharmacother 2021;22:1157-66. [PMID: 33530765 DOI: 10.1080/14656566.2021.1880566] [Reference Citation Analysis]
13 Azevedo H, Ferreira M, Costa RW, Russo V, Russo E, Mascarello A, Guimarães CRW. Preclinical characterization of ACH-000029, a novel anxiolytic compound acting on serotonergic and alpha-adrenergic receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2019;95:109707. [DOI: 10.1016/j.pnpbp.2019.109707] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]